Study of CEP-701 in Treatment of Prostate Cancer

Status:
Completed

Trial end date:
2005-06-01

Target enrollment:

Participant gender:

The purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (PSA) by day 85.

Phase 2

Cephalon